Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Chung‐Han Lee et al.|Nature Genetics|2019Cited by 4.4k
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M. Forde, Drew M. Pardoll, Jamie E. Chaft et al.|New England Journal of Medicine|2018Cited by 2.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerHeather A. Wakelee, Jonathan Spicer, Terufumi Kato et al.|New England Journal of Medicine|2023Cited by 1k
Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain MetastasisManuel Valiente, Joan Massagué, Anna C. Obenauf et al.|Cell|2014Cited by 882
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)Tricia R. Cottrell, Janis M. Taube, Elizabeth D. Thompson et al.|Annals of Oncology|2018Cited by 588